Skip to main content

Table 1 Baseline characteristics of patients

From: The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil

Characteristics Number of patients (n = 216)
Gender, M/F (%male) 123/93 (56.9)
Age (yrs) (mean ± SD) * 53.6 ± 9.0
Initial Weight (Kg) (mean ± SD)* 76.4 ± 14.0
BMI (Kg/m2) (mean ± SD)* 27.5 ± 4.7
Median Aminotrasferase levels. U/L (range)**  
  Baseline Alanine aminotrasferase (ALT) 95 (61–165)
  Baseline Aspartate aminotransferase (AST) 84.5 (52–123)
HCV Genotype, n (%) n = 216
  Genotype 2 12 (5.6)
  Genotype 3 204 (94.4)
Response to previous treatment, n (%) n = 216
  Non-responders 128 (59.3)
  Relapsers 88 (40.7)
Histological diagnosis, n (%)*** n = 196
  Fibrosis stage 0 – 2 47 (24.0)
  Fibrosis stage 3 – 4 149 (76.0)
Baseline serum HCV RNA (IU/mL), n (%)**** n = 155
  < 800.000 55 (35.5)
  ≥ 800.000 100 (64.5)
  1. *Mean ± standard deviation.
  2. **Median (range percentile 25 – 75).
  3. ***Twenty missing (9.3%).
  4. ****Sixty-one missing (28.2%).